COVID-19 Infection in Patients With Hepatocellular Carcinoma

Summary

Since December 2019, a new disease named COVID-19 linked to a new coronavirus, SARS-CoV2 has emerged in China in the city of Wuhan, Hubei province, spreading very quickly to all 5 continents, and responsible for a pandemic. France is the third most affected country in Europe after Italy and Spain. Groups of patients at a higher risk of developing a severe form of COVID-19 have been defined: this include patients with immunosuppressive disease as cancer or patients with advanced cirrhosis of the liver. Coronavirus liver injury had been described with SARS-CoV 1 and MERS-CoV. There is no data on liver damage associated with COVID-19 infection for compensated or decompensated cirrhotic patients. The objectives of this project are to estimate the incidence of COVID-19 in hepatocellular carcinoma population, both hospital and ambulatory, and to study the impact on the frequency of severe forms, the prognosis, but also liver function, and the management of hepatocellular carcinoma, in this context of pandemic

Conditions

• Hepatocellular Carcinoma
• COVID-19

Interventions

DIAGNOSTIC_TEST

nasopharyngeal Covid 19 RT-PCR

nasopharyngeal Covid 19 RT-PCR

Sponsors & Collaborators

• Centre Hospitalier-Universitaire Bondy

  collaborator UNKNOWN

• University Hospital, Bordeaux

  collaborator OTHER

• Centre Hospitalier-Universitaire CLICHY

  collaborator UNKNOWN

• Centre Hospitalier Général CORBEIL-ESSONNE

  collaborator UNKNOWN

• CHU CRETEIL

  collaborator UNKNOWN

• University Hospital, Grenoble

  collaborator OTHER

• University Hospital, Lille

  collaborator OTHER

• Hospices Civils de Lyon

  collaborator OTHER

• Poitiers University Hospital

  collaborator OTHER

• Rennes University Hospital

  collaborator OTHER

• University Hospital, Rouen

  collaborator OTHER

• University Hospital, Toulouse

  collaborator OTHER

• CHU VILLEJUIF

  collaborator UNKNOWN

• Central Hospital, Nancy, France

  collaborator OTHER

• Centre Hospitalier Universitaire de Nice

  collaborator OTHER

• University Hospital, Montpellier

  collaborator OTHER

• Centre Hospitalier Universitaire, Amiens

  lead OTHER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-04-27

Primary Completion

2023-10-01

Completion

2024-10-31

Countries

• France

Study Locations